国产成人三级网址在线看_日韩高清在线毛片_精品国内自产拍在线观看尤物_欧美精品 亚洲日韩_成人黄色影片在线看_国产一区二区播放_国产午夜理论最新电影_日本伊人久久综合_亚洲国产网站视频在线播放_日韩人妻系列无码专区

巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)

Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay)

CCL3; MIP1-A; SCYA3; Chemokine C-C-Motif Ligand 3; Small Inducible Cytokine A3; Homologous To Mouse Mip-1a; Tonsillar Lymphocyte LD78 Alpha Protein

(注:?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) )

  • 巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) 產(chǎn)品包裝(模擬)
  • 巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) 產(chǎn)品包裝(模擬)
  • Certificate 通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

特異性

本試劑盒用于檢測(cè)巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。

回收率

分別于定值血清及血漿樣本中加入一定量的巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。

樣本 回收率范圍(%) 平均回收率(%)
serum(n=5) 79-94 89
EDTA plasma(n=5) 93-101 96
heparin plasma(n=5) 89-101 96
sodium citrate plasma(n=5) 78-98 94

精密度

精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%

線性

在定值血清及血漿樣本內(nèi)加入適量的巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。

樣本 1:2 1:4 1:8 1:16
serum(n=5) 80-96% 98-105% 86-104% 93-102%
EDTA plasma(n=5) 93-101% 91-105% 91-99% 99-105%
heparin plasma(n=5) 88-103% 89-102% 80-103% 91-99%
sodium citrate plasma(n=5) 83-91% 83-90% 92-101% 98-105%

穩(wěn)定性

經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。

實(shí)驗(yàn)流程

1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
    37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。

實(shí)驗(yàn)原理

將巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。

贈(zèng)品

相關(guān)產(chǎn)品

編號(hào) 適用物種:Homo sapiens (Human,人) 應(yīng)用(僅供研究使用,不用于臨床診斷!)
RPA092Hu01 巨噬細(xì)胞炎性蛋白1α(MIP1a)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APA092Hu01 巨噬細(xì)胞炎性蛋白1α(MIP1a)活性蛋白 Cell?culture;?Activity?Assays.
APA092Hu61 巨噬細(xì)胞炎性蛋白1α(MIP1a)活性蛋白 Cell?culture;?Activity?Assays.
EPA092Hu61 巨噬細(xì)胞炎性蛋白1α(MIP1a)真核蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
EPA092Hu51 巨噬細(xì)胞炎性蛋白1α(MIP1a)真核蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA092Hu07 巨噬細(xì)胞炎性蛋白1α(MIP1a)多克隆抗體 WB; IHC; ICC; IP.
PAA092Hu01 巨噬細(xì)胞炎性蛋白1α(MIP1a)多克隆抗體 WB; IHC; ICC; IP.
PAA092Hu06 巨噬細(xì)胞炎性蛋白1α(MIP1a)多克隆抗體 WB; IHC; ICC; IP.
MAA092Hu22 巨噬細(xì)胞炎性蛋白1α(MIP1a)單克隆抗體 WB; IHC; ICC; IP.
SEA092Hu 巨噬細(xì)胞炎性蛋白1α(MIP1a)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA092Hu 巨噬細(xì)胞炎性蛋白1α(MIP1a)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
LMA092Hu 巨噬細(xì)胞炎性蛋白1α(MIP1a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) FLIA Kit for Antigen Detection.
KSA092Hu01 巨噬細(xì)胞炎性蛋白1α(MIP1a)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) Main materials for "Do It (ELISA Kit) Yourself".
PGA092Hu01 巨噬細(xì)胞炎性蛋白1α(MIP1a)引物對(duì) PCR

參考文獻(xiàn)

雜志 參考文獻(xiàn)
Inhalation Toxicology Age influence on hypersensitivity pneumonitis induced in mice by exposure to Pantoea agglomerans [Pubmed: 24044680]
Scientific Reports The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37Ra [Pubmed:26912204]
ActaMedicaMediterranea CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-Α) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH … [57e97ac908aeb34bc08fd41a.pdf]
National Natural Scientific Role of Gut-Derived Endotoxin on Type I Collagen Production in the Rat Pancreas after Chronic Alcohol Exposure [pubmed:29121396]
Pharmacological Reports Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without posttraumatic stress disorder [10.1016/j.pharep.2017.08.008]
NPG?Asia?Materials Molybdenum disulfide/graphene oxide nanocomposites show favorable lung targeting and enhanced drug loading/tumor-killing efficacy with improved?… [Articles:am2017225]
Journal of Immunology?Research Therapeutic Potential of Pien Tze Huang on Experimental Autoimmune Encephalomyelitis Rat [Pubmed:29682587]
Journal of Immunology?Research Cathelicidin LL-37 affects surface and intracellular Toll-like receptor expression in tissue mast cells [Pubmed:29670923]
Pharmacological Reports Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without?… [Pubmed:29339257]
Journal?of?Food?Science CQPC06 Activity Prevents Dextran Sulfate Sodium‐Induced Colitis by Regulating the IL‐8 Pathway [Doi: 10.1111/1750-3841.14346]
Biochemical and Biophysical Research Communications The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion [Pubmed: 30558792]
LIFE SCIENCES Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress [Pubmed: 33227274]
ACTA PHARMACOLOGICA SINICA α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice [Pubmed: 32973325]
Life Sci PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape [Pubmed: 32971102]
Nature Communications A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy [Pubmed: 32332752]
Neoplasia PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1 [34325342]
留言咨詢